Congratulations to DaiichiSankyo on stellar data with trastuzumab deruxtecan (Enhertu) in Her2 low breast cancer. Wonderful news for patients and perhaps the example that all of us working in ADCs strive to achieve. Well done! #adc#antibodydrugconjugate
This year #worldovariancancerday coincides with Mother’s Day. I’m proud of the work @MersanaADC is doing to make a difference for patients fighting this disease.
Congratulations to @DaiichiSankyoUS on a second interesting #antibodydrugconjugate candidate and collaboration with @AstraZenecaUS. Yet another clear sign of renewed and growing interest and excitement for new platforms and next-gen #ADCs https://t.co/JKvGMmekTU
Looking forward to chairing the World ADC summit next week - excited to hear the latest news in the ADC field and share some of ours! #WorldADC#mersana
John McCain was many things – a proud graduate of the Naval Academy, a Senate colleague, a political opponent.
But, to me, more than anything, John was a friend. He will be missed dearly.
ASCO provides clarity around HER-2 FISH indeterminates.
Summary: get IHC.
0-1+= negative, 3+ = positive....if 2+ IHC and no change in ISH by 2nd reviewer, then:
1) ratio <2, copy num > 4 = neg
2) copy num 4-6, ratio <2 = neg
3) copy num >6 and ratio <2 = positive https://t.co/qhhKUO2Zvg
Hot off the e-press: our new book from @SpringerNature on next-generation ADC therapeutics... the culmination of an outstanding collaboration of scientific leaders in the #ADC field.
https://t.co/Ct12HykbhU
@World_ADC